Company Overview - Shenzhen Yimufeng Biotechnology Co., Ltd. is a leading global innovative cell therapy company, with its core product IMC002 being a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, currently in Phase III clinical trials for treating solid tumors [4] - The company also has a first-in-class anti-EpCAM CAR-T cell therapy candidate IMC001 in Phase I/IIa clinical trials, targeting various epithelial-derived tumors [5] - Yimufeng has developed a proprietary manufacturing process for CAR-T therapies that is expected to offer significant cost advantages, addressing key industry pain points [4] Financial Information - The company reported other income and revenue of approximately RMB 3.36 million for the fiscal year 2024, RMB 2.137 million for the nine months ending September 30, 2024, and RMB 2.877 million for the nine months ending September 30, 2025 [6][8] - Research and development expenses were RMB 54.44 million for the fiscal year 2024, RMB 38.574 million for the nine months ending September 30, 2024, and RMB 48.694 million for the nine months ending September 30, 2025 [7][8] Industry Overview - CAR-T therapy is expanding from hematologic malignancies to solid tumors and autoimmune diseases, presenting significant growth opportunities due to the large patient population [9] - The global incidence of gastric cancer is projected to increase from 893.6 thousand cases in 2019 to 1,017.4 thousand cases in 2024, with a compound annual growth rate (CAGR) of 2.6% [14] - In China, the annual incidence of gastric cancer is expected to rise from 329.7 thousand cases in 2019 to 376.1 thousand cases in 2024, with a CAGR of 2.7% [17]
新股消息 | 易慕峰生物递表港交所 为全球领先的创新型细胞治疗公司
Zhi Tong Cai Jing·2026-02-13 00:24